{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:35:35Z","timestamp":1790818535838,"version":"4.1.0"},"reference-count":142,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Research and Development, Personather Ltd.","award":["# 2019\/35\/B\/NZ3\/03577"],"award-info":[{"award-number":["# 2019\/35\/B\/NZ3\/03577"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Among the many oncology therapies, few have generated as much excitement as CAR-T. The success of CAR therapy would not have been possible without the many discoveries that preceded it, most notably, the Nobel Prize-winning breakthroughs in cellular immunity. However, despite the fact that CAR-T already offers not only hope for development, but measurable results in the treatment of hematological malignancies, CAR-T still cannot be safely applied to solid tumors. The reason for this is, among other things, the lack of tumor-specific antigens which, in therapy, threatens to cause a lethal attack of lymphocytes on healthy cells. In the case of hematological malignancies, dangerous complications such as cytokine release syndrome may occur. Scientists have responded to these clinical challenges with molecular switches. They make it possible to remotely control CAR lymphocytes after they have already been administered to the patient. Moreover, they offer many additional capabilities. For example, they can be used to switch CAR antigenic specificity, create logic gates, or produce local activation under heat or light. They can also be coupled with costimulatory domains, used for the regulation of interleukin secretion, or to prevent CAR exhaustion. More complex modifications will probably require a combination of reprogramming (iPSc) technology with genome editing (CRISPR) and allogenic (off the shelf) CAR-T production.<\/jats:p>","DOI":"10.3390\/cells11121910","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T22:00:38Z","timestamp":1655157638000},"page":"1910","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Application and Design of Switches Used in CAR"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6578-1456","authenticated-orcid":false,"given":"Pawe\u0142","family":"G\u0142owacki","sequence":"first","affiliation":[{"name":"Department of Tumor Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7\/9 St., 90-752 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-0970","authenticated-orcid":false,"given":"Piotr","family":"Rieske","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7\/9 St., 90-752 Lodz, Poland"},{"name":"Department of Research and Development Personather Ltd., Inwestycyjna 7, 95-050 Konstantynow Lodzki, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0163-7258(94)90023-X","article-title":"Coley\u2019s Toxins, Tumor Necrosis Factor and Cancer Research: A Historical Perspective","volume":"64","author":"Wiemann","year":"1994","journal-title":"Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T Cell Persistence through ICOS and 4-1BB Costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cellimm.2012.01.002","article-title":"The Road to the Discovery of Dendritic Cells, a Tribute to Ralph Steinman","volume":"273","author":"Rowley","year":"2012","journal-title":"Cell. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2008-07-019307","article-title":"TLRs and Innate Immunity","volume":"113","author":"Beutler","year":"2009","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.ymthe.2017.06.014","article-title":"Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88\/CD40","volume":"25","author":"Foster","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-3083.2008.02114.x","article-title":"The Importance of Mechnikovs Thorn for an Improved Understanding of 21st Century Medicine and Immunology: A View from the Eye","volume":"68","author":"McGonagle","year":"2008","journal-title":"Scand. J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/vim.2019.0184","article-title":"The ABC of Major Histocompatibility Complexes and T Cell Receptors in Health and Disease","volume":"33","author":"Kedzierska","year":"2020","journal-title":"Viral Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wu, L., Brzostek, J., Sankaran, S., Wei, Q., Yap, J., Tan, T.Y.Y., Lai, J., MacAry, P.A., and Gascoigne, N.R.J. (2021). Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell Model. Cancers, 13.","DOI":"10.3390\/cancers13040867"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/eurheartj\/ehaa096","article-title":"Sir Frank Macfarlane Burnet","volume":"41","author":"Nicholls","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.imlet.2015.07.004","article-title":"Peter Brian Medawar and the Discovery of Acquired Immunological Tolerance","volume":"167","author":"Ribatti","year":"2015","journal-title":"Immunol. Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.juro.2006.04.062","article-title":"The First Human Renal Transplants","volume":"176","author":"Barry","year":"2006","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1532\/IJH97.04197","article-title":"Bone Marrow Transplantation from the Personal Viewpoint","volume":"81","author":"Thomas","year":"2005","journal-title":"Int. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-Edited, Donor-Derived Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cells in Paediatric and Adult B-Cell Acute Lymphoblastic Leukaemia: Results of Two Phase 1 Studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-981-13-9367-9_3","article-title":"Structures of immune checkpoints: An overview on the CD28-B7 family","volume":"Volume 1172","author":"Jin","year":"2019","journal-title":"Structural Immunology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms Controlling PD-L1 Expression in Cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 Disruption of PD-1 Enhances Activity of Universal EGFRvIII CAR T Cells in a Preclinical Model of Human Glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chan, L.Y., Dass, S.A., Tye, G.J., Imran, S.A.M., Wan Kamarul Zaman, W.S., and Nordin, F. (2022). CAR-T Cells\/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10040804"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-Negative TGF-\u03b2 Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In Vitro Elimination of Autoreactive B Cells from Rheumatoid Arthritis Patients by Universal Chimeric Antigen Receptor T Cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B Cell Depletion by CD19-Targeted CAR T Cells Is a Highly Effective Treatment for Murine Lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-Based CAR T Cells with Distinct Costimulatory Domains Mitigate HIV Pathogenesis In Vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Al-Utaibi, K.A., Nutini, A., Sohail, A., Arif, R., Tunc, S., and Sait, S.M. (2021). Forecasting the Action of CAR-T Cells against SARS-Corona Virus-II Infection with Branching Process. Model. Earth Syst. Environ., 1\u20139.","DOI":"10.1007\/s40808-021-01312-3"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1007\/s12325-019-01056-8","article-title":"Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia","volume":"36","author":"Li","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rejeski, K., Kunz, W.G., Rudelius, M., B\u00fccklein, V., Blumenberg, V., Schmidt, C., Karschnia, P., Sch\u00f6berl, F., Dimitriadis, K., and von Baumgarten, L. (2021). Severe Candida Glabrata Pancolitis and Fatal Aspergillus Fumigatus Pulmonary Infection in the Setting of Bone Marrow Aplasia after CD19-Directed CAR T-Cell Therapy\u2013a Case Report. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-020-05755-4"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1002\/ajh.25725","article-title":"Allogenic Hematopoietic Stem Cell Transplantation for Prolonged Bone Marrow Aplasia after Chimeric Antigen Receptor (CAR) T-cell Therapy for Relapsed Diffuse Large B-cell Lymphoma","volume":"95","author":"Qasrawi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s10147-020-01699-6","article-title":"Efficacy and Safety of Tisagenlecleucel in Japanese Adult Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"25","author":"Goto","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"18741","DOI":"10.18632\/aging.104058","article-title":"A Comprehensive Analysis of the Fatal Toxic Effects Associated with CD19 CAR-T Cell Therapy","volume":"12","author":"Cai","year":"2020","journal-title":"Aging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.03.005","article-title":"Measuring IL-6 and SIL-6R in Serum from Patients Treated with Tocilizumab and\/or Siltuximab Following CAR T Cell Therapy","volume":"434","author":"Chen","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-Center Experience Using Anakinra for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e001466","DOI":"10.1136\/jitc-2020-001466","article-title":"Blockade of AIM2 Inflammasome or A1-AR Ameliorates IL-1\u03b2 Release and Macrophage-Mediated Immunosuppression Induced by CAR-T Treatment","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.2019001859","article-title":"A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor\u2013Positive Cells","volume":"135","author":"Ruella","year":"2020","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of Cytokine Release Syndrome and Neurotoxicity Related to CAR-T Cell Therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient Rest Restores Functionality in Exhausted CAR-T Cells through Epigenetic Remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1172\/JCI133215","article-title":"Single Residue in CD28-Costimulated CAR-T Cells Limits Long-Term Persistence and Antitumor Durability","volume":"130","author":"Guedan","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acssynbio.9b00476","article-title":"A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology","volume":"9","author":"Lee","year":"2020","journal-title":"ACS Synth. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ymthe.2020.06.004","article-title":"Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo","volume":"28","author":"Richman","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"24866","DOI":"10.1074\/jbc.M703902200","article-title":"A Directed Approach for Engineering Conditional Protein Stability Using Biologically Silent Small Molecules","volume":"282","author":"Chen","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The Tyrosine Kinase Inhibitor Dasatinib Acts as a Pharmacologic on\/off Switch for CAR T Cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Juillerat, A., Tkach, D., Busser, B.W., Temburni, S., Valton, J., Duclert, A., Poirot, L., Depil, S., and Duchateau, P. (2019). Modulation of Chimeric Antigen Receptor Surface Expression by a Small Molecule Switch. BMC Biotechnol., 19.","DOI":"10.1186\/s12896-019-0537-3"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"802812.e6","DOI":"10.1016\/j.chembiol.2020.11.012","article-title":"An IMiD-Inducible Degron Provides Reversible Regulation for Chimeric Antigen Receptor Expression and Activity","volume":"28","author":"Carbonneau","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"eabb6295","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-Switch Chimeric Antigen Receptors Controlled by Lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0958-1669(02)00361-0","article-title":"Latest Developments and in Vivo Use of the Tet System: Ex Vivo and in Vivo Delivery of Tetracycline-Regulated Genes","volume":"13","author":"Corbel","year":"2002","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1566523216666160524144041","article-title":"Tet-On Systems for Doxycycline-Inducible Gene Expression","volume":"16","author":"Tenenbaum","year":"2016","journal-title":"CGT"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","article-title":"A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration","volume":"4","author":"Sakemura","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gu, X., He, D., Li, C., Wang, H., and Yang, G. (2018). Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113455"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fcell.2019.00233","article-title":"Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Drent, E., Poels, R., Mulders, M.J., van de Donk, N.W.C.J., Themeli, M., Lokhorst, H.M., and Mutis, T. (2018). Feasibility of Controlling CD38-CAR T Cell Activity with a Tet-on Inducible CAR Design. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197349"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.1038\/s41598-020-70022-0","article-title":"Optimisation of Tet-On Inducible Systems for Sleeping Beauty-Based Chimeric Antigen Receptor (CAR) Applications","volume":"10","author":"Poudel","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.celrep.2018.09.026","article-title":"Light Control of the Tet Gene Expression System in Mammalian Cells","volume":"25","author":"Yamada","year":"2018","journal-title":"Cell Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eaay9209","DOI":"10.1126\/sciadv.aay9209","article-title":"Engineering Light-Controllable CAR T Cells for Cancer Immunotherapy","volume":"6","author":"Huang","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/acssynbio.9b00175","article-title":"An AND-Gated Drug and Photoactivatable Cre- LoxP System for Spatiotemporal Control in Cell-Based Therapeutics","volume":"8","author":"Allen","year":"2019","journal-title":"ACS Synth. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1097\/HS9.0000000000000533","article-title":"Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells","volume":"5","author":"Karschnia","year":"2021","journal-title":"HemaSphere"},{"key":"ref_59","first-page":"581","article-title":"Penetration Profiles of Visible and Near-Infrared Lasers and Light-Emitting Diode Light Through the Head Tissues in Animal and Human Species: A Review of Literature","volume":"37","author":"Salehpour","year":"2019","journal-title":"Photobiomodul. Photomed. Laser Surg."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hong, A.-R., Han, J.S., Kang, G., Ko, H., and Jang, H.S. (2020). Bright Blue, Green, and Red Luminescence from Dye-Sensitized Core@Shell Upconversion Nanophosphors under 800 Nm Near-Infrared Light. Materials, 13.","DOI":"10.3390\/ma13235338"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2000055","DOI":"10.1002\/adma.202000055","article-title":"Designing Stimuli-Responsive Upconversion Nanoparticles That Exploit the Tumor Microenvironment","volume":"32","author":"Ovais","year":"2020","journal-title":"Adv. Mater."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Kotter, B., Engert, F., Krueger, W., Roy, A., Rawashdeh, W.A., Cordes, N., Drees, B., Webster, B., Werchau, N., and Lock, D. (2021). Titratable Pharmacological Regulation of CAR T Cells Using Zinc Finger-Based Transcription Factors. Cancers, 13.","DOI":"10.3390\/cancers13194741"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e2106612118","DOI":"10.1073\/pnas.2106612118","article-title":"Engineering Genetic Devices for in Vivo Control of Therapeutic T Cell Activity Triggered by the Dietary Molecule Resveratrol","volume":"118","author":"Yang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1182\/blood.2021010784","article-title":"Utility of a Safety Switch to Abrogate CD19.CAR T-Cell\u2013Associated Neurotoxicity","volume":"137","author":"Foster","year":"2021","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41417-020-00284-3","article-title":"Overcoming Target Epitope Masking Resistance That Can Occur on Low-Antigen-Expresser AML Blasts after IL-1RAP Chimeric Antigen Receptor T Cell Therapy Using the Inducible Caspase 9 Suicide Gene Safety Switch","volume":"28","author":"Warda","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4939-8922-5_5","article-title":"Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy","volume":"Volume 1895","year":"2019","journal-title":"Suicide Gene Therapy"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","article-title":"CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor\u2013Engineered T Cells","volume":"79","author":"Warda","year":"2019","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.omto.2018.12.009","article-title":"Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches","volume":"12","author":"Duong","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord Blood NK Cells Engineered to Express IL-15 and a CD19-Targeted CAR Show Long-Term Persistence and Potent Antitumor Activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"You, Y. (2011). Suicide Gene Therapy by Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK). Targets in Gene Therapy, InTech.","DOI":"10.5772\/1012"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fphar.2015.00095","article-title":"Improving the Safety of Cell Therapy with the TK-Suicide Gene","volume":"6","author":"Greco","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_77","first-page":"1","article-title":"Gene Therapy with HSV1-Sr39TK\/GCV Exhibits a Stronger Therapeutic Efficacy Than HSV1-TK\/GCV in Rat C6 Glioma Cells","volume":"2013","author":"Li","year":"2013","journal-title":"Sci. World J."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Zhan, H., Gilmour, K., Chan, L., Farzaneh, F., McNicol, A.M., Xu, J.-H., Adams, S., Fehse, B., Veys, P., and Thrasher, A. (2013). Production and First-in-Man Use of T Cells Engineered to Express a HSVTK-CD34 Sort-Suicide Gene. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077106"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2018.00507","article-title":"Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene","volume":"9","author":"Casucci","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"734246","DOI":"10.3389\/fimmu.2021.734246","article-title":"Depletion of T Cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B","volume":"12","author":"Klopp","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-19-3579","article-title":"PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors","volume":"80","author":"Murty","year":"2020","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s11307-016-0971-8","article-title":"Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography","volume":"18","author":"Najjar","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"104342","DOI":"10.1016\/j.cellimm.2021.104342","article-title":"A Transgene-Encoded Truncated Human Epidermal Growth Factor Receptor for Depletion of Anti- B-Cell Maturation Antigen CAR-T Cells","volume":"363","author":"Wang","year":"2021","journal-title":"Cell. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/hum.2018.180","article-title":"A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor\u2013Modified Hematopoietic Stem Cells for Cancer Therapy","volume":"30","author":"Kao","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jconrel.2020.08.047","article-title":"Impact of Blood-Brain Barrier Permeabilization Induced by Ultrasound Associated to Microbubbles on the Brain Delivery and Kinetics of Cetuximab: An ImmunoPET Study Using 89Zr-Cetuximab","volume":"328","author":"Tran","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2174\/1389450115666141029234644","article-title":"Intrathecal Rituximab Therapy in Multiple Sclerosis: Review of Evidence Supporting the Need for Future Trials","volume":"15","author":"Bonnan","year":"2014","journal-title":"CDT"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant Cerebral Cytokine Release Syndrome in CD19-Directed Chimeric Antigen Receptor-Modified T Cell Therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_90","first-page":"285","article-title":"The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System","volume":"39","author":"Li","year":"2021","journal-title":"Cancer Investig."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.32663","article-title":"In Vitro Elimination of Epidermal Growth Factor Receptor-overexpressing Cancer Cells by CD32A-chimeric Receptor T Cells in Combination with Cetuximab or Panitumumab","volume":"146","author":"Caratelli","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Relapsed B Cell Malignancies: A Phase 1 Dose Escalation and Expansion Trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of Concept for a Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed\/Refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.2147\/OTT.S245169","article-title":"Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab\u00ae","volume":"13","author":"Jureczek","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/s41467-019-10565-7","article-title":"Regulation of CAR T Cell-Mediated Cytokine Release Syndrome-like Toxicity Using Low Molecular Weight Adapters","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e1368604","DOI":"10.1080\/2162402X.2017.1368604","article-title":"MSA2 Affinity-Enhanced Biotin-Binding CAR T Cells for Universal Tumor Targeting","volume":"7","author":"Lohmueller","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1158\/0008-5472.CAN-18-1834","article-title":"Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors","volume":"79","author":"Lee","year":"2019","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/gutjnl-2018-316595","article-title":"Switchable CAR-T Cells Mediate Remission in Metastatic Pancreatic Ductal Adenocarcinoma","volume":"68","author":"Raj","year":"2019","journal-title":"Gut"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","article-title":"Switchable Control over in Vivo CAR T Expansion, B Cell Depletion, and Induction of Memory","volume":"115","author":"Viaud","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41598-020-59082-4","article-title":"\u201cUniCAR\u201d-Modified off-the-Shelf NK-92 Cells for Targeting of GD2-Expressing Tumour Cells","volume":"10","author":"Mitwasi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T Cells on and off: A Novel Modular Platform for Retargeting of T Cells to AML Blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"12178","DOI":"10.1002\/anie.202005432","article-title":"Chemically Programmable and Switchable CAR-T Therapy","volume":"59","author":"Qi","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.chembiol.2020.10.004","article-title":"Photoswitchable CAR-T Cell Function In Vitro and In Vivo via a Cleavable Mediator","volume":"28","author":"Zhang","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13046-020-01572-4","article-title":"Extended Half-Life Target Module for Sustainable UniCAR T-Cell Treatment of STn-Expressing Cancers","volume":"39","author":"Loureiro","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1945804","DOI":"10.1080\/2162402X.2021.1945804","article-title":"Evaluation of Switch-Mediated Costimulation in Trans on Universal CAR-T Cells (UniCAR) Targeting CD123-Positive AML","volume":"10","author":"Meyer","year":"2021","journal-title":"OncoImmunology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"14926","DOI":"10.1073\/pnas.1911154117","article-title":"A Conformation-Specific ON-Switch for Controlling CAR T Cells with an Orally Available Drug","volume":"117","author":"Zajc","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-Negative Myeloid Phenotype Allows Immune Escape of MLL-Rearranged B-ALL from CD19 CAR-T-Cell Therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-Mediated Activation and Retargeting of CAR-T Cells for B-Cell Malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"638639","DOI":"10.3389\/fimmu.2021.638639","article-title":"JAK\/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting from a Dual AND\/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment","volume":"12","author":"Khanali","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering Advanced Logic and Distributed Computing in Human CAR Immune Cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2741\/4703","article-title":"GITR Domain inside CAR Co-Stimulates Activity of CAR-T Cells against Cancer","volume":"23","author":"Golubovskaya","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.omto.2021.08.014","article-title":"Novel Two-Chain Structure Utilizing KIRS2\/DAP12 Domain Improves the Safety and Efficacy of CAR-T Cells in Adults with r\/r B-ALL","volume":"23","author":"Sun","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e20192203","DOI":"10.1084\/jem.20192203","article-title":"Optimized Gene Engineering of Murine CAR-T Cells Reveals the Beneficial Effects of IL-15 Coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.cbpa.2015.09.003","article-title":"Chemically Induced Dimerization: Reversible and Spatiotemporal Control of Protein Function in Cells","volume":"28","author":"Klewer","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","article-title":"Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models","volume":"7","author":"Mata","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.1012501","article-title":"TLR Agonists: Our Best Frenemy in Cancer Immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Isogawa, M., Chung, J., Murata, Y., Kakimi, K., and Chisari, F.V. (2013). CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated Exhaustion. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003490"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","article-title":"Constitutively Active MyD88\/CD40 Costimulation Enhances Expansion and Efficacy of Chimeric Antigen Receptor T Cells Targeting Hematological Malignancies","volume":"33","author":"Chang","year":"2019","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e136093","DOI":"10.1172\/jci.insight.136093","article-title":"MyD88\/CD40 Signaling Retains CAR T Cells in a Less Differentiated State","volume":"5","author":"Prinzing","year":"2020","journal-title":"JCI Insight"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/bloodadvances.2020001510","article-title":"Inducible MyD88\/CD40 Synergizes with IL-15 to Enhance Antitumor Efficacy of CAR-NK Cells","volume":"4","author":"Wang","year":"2020","journal-title":"Blood Adv."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019001645","article-title":"Specific Stimulation of T Lymphocytes with Erythropoietin for Adoptive Immunotherapy","volume":"135","author":"Vinanica","year":"2020","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"eabg6986","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A Human Orthogonal IL-2 and IL-2R\u03b2 System Enhances CAR T Cell Expansion and Antitumor Activity in a Murine Model of Leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41551-021-00781-2","article-title":"Enhanced Intratumoural Activity of CAR T Cells Engineered to Produce Immunomodulators under Photothermal Control","volume":"5","author":"Miller","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T Cells Exert Potent Graft-versus-Lymphoma Activity with Diminished Graft-versus-Host Activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3389\/fimmu.2018.01409","article-title":"Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy","volume":"9","author":"Fisher","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.5966\/sctm.2015-0049","article-title":"Targeted Disruption of the \u03b2 2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells","volume":"4","author":"Wang","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates IPSCs with Enhanced Immune Compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41232-020-00132-9","article-title":"Current Status and Future Perspectives of HLA-Edited Induced Pluripotent Stem Cells","volume":"40","author":"Koga","year":"2020","journal-title":"Inflamm. Regener."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"662360","DOI":"10.3389\/fimmu.2021.662360","article-title":"Fit-For-All IPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice with NK Cell Immunity","volume":"12","author":"Flahou","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.hoc.2017.06.007","article-title":"Nonintegrating Gene Therapy Vectors","volume":"31","author":"Athanasopoulos","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/hum.2006.17.253","article-title":"Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors","volume":"17","author":"Baum","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cmi.2016.02.013","article-title":"The Benefits of Integration","volume":"22","author":"Ciuffi","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical Use of Lentiviral Vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"ref_138","first-page":"4235","article-title":"PiggyBac Transposon System Modification of Primary Human T Cells","volume":"69","author":"Saha","year":"2012","journal-title":"JoVE"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Magnani, C.F., Tettamanti, S., Alberti, G., Pisani, I., Biondi, A., Serafini, M., and Gaipa, G. (2020). Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?. Cells, 9.","DOI":"10.3390\/cells9061337"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/gt.2014.104","article-title":"The Tol2 Transposon System Mediates the Genetic Engineering of T-Cells with CD19-Specific Chimeric Antigen Receptors for B-Cell Malignancies","volume":"22","author":"Tsukahara","year":"2015","journal-title":"Gene Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.omtm.2019.12.020","article-title":"CAR T Cell Generation by PiggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions","volume":"17","author":"Bishop","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/mt.2014.254","article-title":"Hybrid Nonviral\/Viral Vector Systems for Improved PiggyBac DNA Transposon In Vivo Delivery","volume":"23","author":"Cooney","year":"2015","journal-title":"Mol. Ther."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/12\/1910\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:28:41Z","timestamp":1760138921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/12\/1910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":142,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cells11121910"],"URL":"https:\/\/doi.org\/10.3390\/cells11121910","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}